Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
As your pet ages however, the performance of the kidneys can diminish
How long does it take to get results after the treatment
Aging Pathobiology and Therapeutics (2022) 4
Your provider will give you a powder that youll mix with sterile water and inject into a fatty area, such as your belly or thigh, using a very thin needle
Healthy-looking skin, hair, and nails often start with proper nutrition and hydration